Danish Medicines Agency strengthens its organisational foundation to prepare for tomorrow's tasks

As of 1 January 2026, a new structure will facilitate cross-disciplinary collaboration and prepare the agency for tomorrow’s tasks within especially four strategic areas. The new structure is also welcoming a new division for preparedness and supply.

To best fulfil our regulatory tasks of ensuring effective, safe and available medicines and safe medical devices, the Danish Medicines Agency has decided to change its organisational structure as of 1 January 2026.

“At the Danish Medicines Agency, we want to develop in step with the world around us, so that we may deliver on the high demand for our expertise – now and in the future. That's why we are changing our organisational structure to apply our expertise and skills more effectively and in more obvious ways to achieve the most synergy, knowledge sharing and professional development”, says Nils Falk Bjerregaard, Director General of the Danish Medicines Agency, while adding:

“As part of our new structure, we have selected four strategic areas in which the agency will significantly strengthen its internal collaboration. Here, cross-disciplinary competence is central to ensuring that we take a holistic approach to our tasks and that more fields of expertise collaborate on each agenda – whether national, European or international in nature.

The four strategic areas are: Organisation of the Healthcare System, Life Science & Innovation, Advanced Data Analysis & RWE (Real World Evidence) and EU & International.

Among the structural changes, the Danish Medicines Agency is creating a new division for preparedness and supply, thereby pooling and strengthening its resources within an area that attracts considerable public attention and is highly relevant to society.

The new organisational structure will not affect our collaboration and activities with our partners, which will continue as before.